PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 12241832-16 2002 Although the role of losartan in patients intolerant of ACE inhibition is not clearly defined, it can be considered in such patients. Losartan 21-29 angiotensin I converting enzyme Homo sapiens 56-59 12222553-6 2002 We report angioedema associated with losartan (an ARB) in a patient who had experienced angioedema secondary to enalapril (an ACE inhibitor). Losartan 37-45 angiotensin I converting enzyme Homo sapiens 126-129 11811369-5 2001 A significant improvement in endothelial dysfunction may be observed in hypertensive patients after prolonged treatment with ACE inhibitors (cilazapril, lisinopril), calcium entry blockers (nifedipine), and angiotensin II receptor blockers (losartan), while atenolol and hydrochlorotiazide proved to be ineffective in this regard despite similar blood pressure reductions. Losartan 241-249 angiotensin I converting enzyme Homo sapiens 125-128 11877567-13 2002 Thus, proteinuric patients with renal failure, despite maximal ACE inhibition, had increased urinary levels of TGF-beta1 that improved over 1 month of add-on therapy with losartan. Losartan 171-179 angiotensin I converting enzyme Homo sapiens 63-66 11588528-0 2001 T-lymphocyte and plasma angiotensin-converting enzyme activity during enalapril and losartan administration in humans. Losartan 84-92 angiotensin I converting enzyme Homo sapiens 24-53 11588528-1 2001 This study evaluated the long-term effects of the angiotensin-converting enzyme inhibitor enalapril and the angiotensin II type 1 receptor antagonist losartan on the angiotensin-converting enzyme activity in T lymphocytes and plasma in patients with essential hypertension. Losartan 150-158 angiotensin I converting enzyme Homo sapiens 166-195 11211003-3 2001 This pattern of abnormalities is similar to those seen in exposure to angiotensin-converting-enzyme (ACE) inhibitors during pregnancy, and were probably caused by losartan. Losartan 163-171 angiotensin I converting enzyme Homo sapiens 70-99 11801934-3 2001 Angiotensin II receptor antagonists (AT2 blockers), such as losartan potassium (Cozaar; Merck & Co., West Point, PA), are a new class of antihypertensives developed in part to eliminate cough and angioedema associated with ACE inhibitors. Losartan 60-78 angiotensin I converting enzyme Homo sapiens 227-230 11801934-3 2001 Angiotensin II receptor antagonists (AT2 blockers), such as losartan potassium (Cozaar; Merck & Co., West Point, PA), are a new class of antihypertensives developed in part to eliminate cough and angioedema associated with ACE inhibitors. Losartan 80-86 angiotensin I converting enzyme Homo sapiens 227-230 11675956-0 2001 Effects of losartan on blood pressure and humoral factors in a patient who suffered from anaphylactoid reactions when treated with ACE inhibitors during LDL apheresis. Losartan 11-19 angiotensin I converting enzyme Homo sapiens 131-134 11211003-3 2001 This pattern of abnormalities is similar to those seen in exposure to angiotensin-converting-enzyme (ACE) inhibitors during pregnancy, and were probably caused by losartan. Losartan 163-171 angiotensin I converting enzyme Homo sapiens 101-104 10483973-1 1999 OBJECTIVES: The antiarrhythmic efficacies of the competitive angiotensin II (AII) antagonist losartan, losartan"s more potent noncompetitive AII antagonist human metabolite EXP3174 and the angiotensin-converting enzyme inhibitor captopril were assessed in a canine model of recent myocardial infarction. Losartan 93-101 angiotensin I converting enzyme Homo sapiens 189-218 12426159-6 2001 Losartan and lisinopril both decreased ACE mRNA expression levels that were positively correlated with the difference of the diastolic blood pressure whereas nisodipine elevated ACE mRNA expression, showing inverse correlation to the difference of thediastolic blood pressure. Losartan 0-8 angiotensin I converting enzyme Homo sapiens 39-42 12426159-6 2001 Losartan and lisinopril both decreased ACE mRNA expression levels that were positively correlated with the difference of the diastolic blood pressure whereas nisodipine elevated ACE mRNA expression, showing inverse correlation to the difference of thediastolic blood pressure. Losartan 0-8 angiotensin I converting enzyme Homo sapiens 178-181 11967824-10 2000 Treatment with the AT(1)-receptor antagonist losartan led to a slight improvement in microvascular endothelial function, but pre-treatment with losartan blunted the vascular effect of quinapril, suggesting that the combination of ACE inhibition and AT(1)-receptor antagonism may not exert a synergistic benefical impact on the coronary vasculature. Losartan 45-53 angiotensin I converting enzyme Homo sapiens 230-233 11967824-10 2000 Treatment with the AT(1)-receptor antagonist losartan led to a slight improvement in microvascular endothelial function, but pre-treatment with losartan blunted the vascular effect of quinapril, suggesting that the combination of ACE inhibition and AT(1)-receptor antagonism may not exert a synergistic benefical impact on the coronary vasculature. Losartan 144-152 angiotensin I converting enzyme Homo sapiens 230-233 11054627-2 2000 METHODS: Twenty patients with mild to moderate heart failure and maximally treated with an ACE inhibitor were randomly assigned to losartan or placebo. Losartan 131-139 angiotensin I converting enzyme Homo sapiens 91-94 11054627-6 2000 CONCLUSIONS: In patients with mild to moderate heart failure already maximally treated with an ACE inhibitor, additional treatment with losartan is well tolerated, but we have not observed any significant improvement in exercise capacity, quality of life, central and regional hemodynamics, or neurohormones. Losartan 136-144 angiotensin I converting enzyme Homo sapiens 95-98 10821361-1 2000 BACKGROUND: The ELITE study showed an association between the angiotensin II antagonist losartan and an unexpected survival benefit in elderly heart-failure patients, compared with captopril, an angiotensin-converting-enzyme (ACE) inhibitor. Losartan 88-96 angiotensin I converting enzyme Homo sapiens 226-229 9829449-1 1998 The objective of this study was to determine the incidence of dry cough in hypertensive patients with a history of angiotensin-converting enzyme (ACE) inhibitor-induced cough after treatment with losartan (an angiotensin II-receptor antagonist), lisinopril (an ACE inhibitor), or placebo. Losartan 196-204 angiotensin I converting enzyme Homo sapiens 146-149 10051289-12 1999 CONCLUSIONS: Losartan enhances peak exercise capacity and alleviates symptoms in patients with CHF who are severely symptomatic despite treatment with maximally recommended or tolerated doses of ACE inhibitors. Losartan 13-21 angiotensin I converting enzyme Homo sapiens 195-198 10410812-5 1999 The administration of the ACE inhibitor neutralised the expected increases in plasma Angiotensin II values due to the losartan. Losartan 118-126 angiotensin I converting enzyme Homo sapiens 26-29 10336919-0 1999 Does the addition of losartan improve the beneficial effects of ACE inhibitors in patients with anterior myocardial infarction? Losartan 21-29 angiotensin I converting enzyme Homo sapiens 64-67 9793603-7 1998 We found only one published case in which losartan was used without deterioration in renal function in patients who developed renal dysfunction while taking an ACE inhibitor, although underreporting of such cases would be expected. Losartan 42-50 angiotensin I converting enzyme Homo sapiens 160-163 9793603-8 1998 There was one case of renal dysfunction with losartan after a lack of renal dysfunction while the patient was taking an ACE inhibitor. Losartan 45-53 angiotensin I converting enzyme Homo sapiens 120-123 9793603-14 1998 Furthermore, case reports suggest that, as with ACE inhibitors, losartan should be avoided in patients with bilateral renal artery stenosis and in patients with unilateral renal artery stenosis in a solitary kidney. Losartan 64-72 angiotensin I converting enzyme Homo sapiens 48-51 9829449-10 1998 These results demonstrate that the incidence, severity, and frequency of dry cough in patients with a history of ACE inhibitor-induced dry cough are significantly lower in those treated with losartan than in those treated with lisinopril and are similar to the incidence, severity, and frequency of dry cough in those receiving placebo. Losartan 191-199 angiotensin I converting enzyme Homo sapiens 113-116 9723827-0 1998 Start of therapy with the angiotensin II antagonist losartan after immediate switch from pretreatment with an ACE inhibitor. Losartan 52-60 angiotensin I converting enzyme Homo sapiens 110-113 9723827-9 1998 During the 6 weeks double-blind therapy, 9% of L patients experienced at least one adverse event, compared with 16% of patients with C. CONCLUSIONS: In this study the angiotensin II antagonist losartan was effective and generally well tolerated when administered immediately after pretreatment with an ACE inhibitor. Losartan 193-201 angiotensin I converting enzyme Homo sapiens 302-305 9335416-2 1997 Accordingly, the blood-pressure response and safety of combining AT1-receptor blockade with losartan for ACE inhibition were evaluated in patients with congestive heart failure who were already treated with maximally recommended or tolerated doses of an ACE inhibitor. Losartan 92-100 angiotensin I converting enzyme Homo sapiens 105-108 9430872-4 1997 In 10 patients, losartan therapy was initiated after treatment with ACE inhibitors which was discontinued due to adverse reactions (Group A). Losartan 16-24 angiotensin I converting enzyme Homo sapiens 68-71 9316528-2 1997 OBJECTIVES: This study was designed to determine 1) whether 12-week oral administration of losartan, an angiotensin II receptor antagonist, in patients with heart failure is well tolerated; and 2) whether functional capacity and clinical status of patients with heart failure in whom treatment with an angiotensin-converting enzyme (ACE) inhibitor is replaced with losartan for 12 weeks will remain similar to that noted in patients in whom treatment with an ACE inhibitor is continued. Losartan 91-99 angiotensin I converting enzyme Homo sapiens 302-331 9316528-2 1997 OBJECTIVES: This study was designed to determine 1) whether 12-week oral administration of losartan, an angiotensin II receptor antagonist, in patients with heart failure is well tolerated; and 2) whether functional capacity and clinical status of patients with heart failure in whom treatment with an angiotensin-converting enzyme (ACE) inhibitor is replaced with losartan for 12 weeks will remain similar to that noted in patients in whom treatment with an ACE inhibitor is continued. Losartan 91-99 angiotensin I converting enzyme Homo sapiens 333-336 9316528-2 1997 OBJECTIVES: This study was designed to determine 1) whether 12-week oral administration of losartan, an angiotensin II receptor antagonist, in patients with heart failure is well tolerated; and 2) whether functional capacity and clinical status of patients with heart failure in whom treatment with an angiotensin-converting enzyme (ACE) inhibitor is replaced with losartan for 12 weeks will remain similar to that noted in patients in whom treatment with an ACE inhibitor is continued. Losartan 91-99 angiotensin I converting enzyme Homo sapiens 459-462 9335416-8 1997 Combining AT1-receptor blockade with losartan to maximally recommended or tolerated ACE inhibition appears safe and leads to further vasodilatation in symptomatic patients with congestive heart failure. Losartan 37-45 angiotensin I converting enzyme Homo sapiens 84-87 9205848-13 1997 Angioedema, a rare but life-threatening adverse effect of ACE inhibitors, has also been associated with losartan. Losartan 104-112 angiotensin I converting enzyme Homo sapiens 58-61 9211022-6 1997 In patients who develop cough due to an ACE inhibitor, consideration should be given to an angiotensin II type 1 receptor blocking agent, such as losartan. Losartan 146-154 angiotensin I converting enzyme Homo sapiens 40-43 9160080-2 1997 We report the case of a hemodialysis patient who previously had angioedema after therapy with ACE inhibitors and again had angioedema while taking losartan. Losartan 147-155 angiotensin I converting enzyme Homo sapiens 94-97 9160080-3 1997 We suggest caution in using losartan in patients with known sensitivity to ACE inhibitors manifested by angioedema. Losartan 28-36 angiotensin I converting enzyme Homo sapiens 75-78 9089428-7 1997 The specific, selective angiotensin II receptor antagonist losartan is associated with a decrease in the incidence of cough in patients with previous ACE inhibitor-induced cough. Losartan 59-67 angiotensin I converting enzyme Homo sapiens 150-153 18800451-14 1995 Therefore, with respect to therapeutic efficacy, results in animal models indicate that losartan will display the beneficial pharmacology of ACE inhibitors without the detrimental side effects attributed to kinin potentiation. Losartan 88-96 angiotensin I converting enzyme Homo sapiens 141-144 8583482-7 1995 The specific selective AT1 angiotensin II receptor antagonist losartan is significantly less likely than lisinopril to cause cough in patients who previously have had ACE inhibitor cough. Losartan 62-70 angiotensin I converting enzyme Homo sapiens 167-170 8583483-8 1995 In particular cough, a relatively common side-effect of ACE inhibitors, has been shown to be significantly less common during losartan treatment. Losartan 126-134 angiotensin I converting enzyme Homo sapiens 56-59 7664216-9 1995 Results from the prospective study reported in the present manuscript demonstrate that the higher specificity of the type I Ang II receptor antagonist losartan is associated with a significantly lower incidence of cough than seen with ACE inhibitors. Losartan 151-159 angiotensin I converting enzyme Homo sapiens 235-238 7664216-10 1995 Losartan thus represents a potential new treatment for hypertensive patients in whom ACE inhibition or Ang II receptor antagonists are indicated, but who develop cough with ACE inhibitors. Losartan 0-8 angiotensin I converting enzyme Homo sapiens 85-88 7664216-10 1995 Losartan thus represents a potential new treatment for hypertensive patients in whom ACE inhibition or Ang II receptor antagonists are indicated, but who develop cough with ACE inhibitors. Losartan 0-8 angiotensin I converting enzyme Homo sapiens 173-176 18800451-3 1995 DIFFERENCES BETWEEN LOSARTAN AND ACE INHIBITORS: Pharmacological differences between ACE inhibitors and losartan could affect comparative efficacy and/or safety. Losartan 20-28 angiotensin I converting enzyme Homo sapiens 85-88 18800451-3 1995 DIFFERENCES BETWEEN LOSARTAN AND ACE INHIBITORS: Pharmacological differences between ACE inhibitors and losartan could affect comparative efficacy and/or safety. Losartan 104-112 angiotensin I converting enzyme Homo sapiens 33-36 9010643-19 1997 Losartan potassium is likely to be used in patients who are intolerant of ACE inhibitors, but its future in the management of hypertension will depend on long term tolerability studies and data on its effects beyond simple blood pressure control. Losartan 0-18 angiotensin I converting enzyme Homo sapiens 74-77 8792950-14 1996 Losartan may be an alternative for patients who cannot tolerate ACE inhibitors. Losartan 0-8 angiotensin I converting enzyme Homo sapiens 64-67 18800454-1 1995 INTRODUCTION: Losartan potassium, an orally active, highly selective AT1 angiotensin II receptor inhibitor, effectively reduces blood pressure by direct receptor blockade, thereby lessening the likelihood of angiotensin converting enzyme (ACE) inhibitor-associated side effects such as dry cough or possibly angioedema. Losartan 14-32 angiotensin I converting enzyme Homo sapiens 208-237 18800454-1 1995 INTRODUCTION: Losartan potassium, an orally active, highly selective AT1 angiotensin II receptor inhibitor, effectively reduces blood pressure by direct receptor blockade, thereby lessening the likelihood of angiotensin converting enzyme (ACE) inhibitor-associated side effects such as dry cough or possibly angioedema. Losartan 14-32 angiotensin I converting enzyme Homo sapiens 239-242 18800461-5 1995 A dry cough was reported by 8.8% of patients treated with angiotensin converting enzyme (ACE) inhibitors, statistically greater than that reported in patients treated with losartan and placebo, 3.1 and 2.6%, respectively (P < 0.001, losartan versus ACE inhibitors). Losartan 236-244 angiotensin I converting enzyme Homo sapiens 58-87 34529122-9 2021 Soluble ACE2 was higher in patients treated with angiotensin receptors blockers and beta-blockers, accordingly with losartan and metoprolol upregulation of ACE1 and ACE2 in HUVECs. Losartan 116-124 angiotensin I converting enzyme Homo sapiens 156-160 1290620-4 1992 Preliminary inpatient studies have shown that after 5 days of treatment, losartan--in doses of 50, 100, and 150 mg--is significantly more effective than placebo in decreasing blood pressure, and has efficacy similar to that of the angiotensin-converting enzyme (ACE) inhibitor enalapril. Losartan 73-81 angiotensin I converting enzyme Homo sapiens 262-265 7634303-6 1994 Losartan is the first of a new class of orally active, nonpeptide Ang II receptor antagonists able to very specifically and selectively inhibit the RAS while lacking the agonistic effects of the peptide receptor antagonists, e.g. sarlasin, or the bradykinin potentiating effects of the angiotensin converting enzyme (ACE) inhibitors. Losartan 0-8 angiotensin I converting enzyme Homo sapiens 286-315 7634303-6 1994 Losartan is the first of a new class of orally active, nonpeptide Ang II receptor antagonists able to very specifically and selectively inhibit the RAS while lacking the agonistic effects of the peptide receptor antagonists, e.g. sarlasin, or the bradykinin potentiating effects of the angiotensin converting enzyme (ACE) inhibitors. Losartan 0-8 angiotensin I converting enzyme Homo sapiens 317-320 7634303-7 1994 Virtually all of the known actions of Ang II, e.g. those defined by Ang II itself, saralasin, ACE or renin-inhibitors are blocked by losartan, emphasizing the major role of this distinct Ang II receptor subtype in mediating the responses of Ang II. Losartan 133-141 angiotensin I converting enzyme Homo sapiens 94-97 7706699-2 1994 OBJECTIVE: To compare the incidence of cough in patients with a history of angiotensin converting enzyme (ACE) inhibitor-related cough who received losartan [a type 1 angiotensin II (Ang II) receptor antagonist], lisinopril (an ACE inhibitor) or hydrochlorothiazide (a diuretic). Losartan 148-156 angiotensin I converting enzyme Homo sapiens 75-104 7706699-2 1994 OBJECTIVE: To compare the incidence of cough in patients with a history of angiotensin converting enzyme (ACE) inhibitor-related cough who received losartan [a type 1 angiotensin II (Ang II) receptor antagonist], lisinopril (an ACE inhibitor) or hydrochlorothiazide (a diuretic). Losartan 148-156 angiotensin I converting enzyme Homo sapiens 106-109 7706699-10 1994 CONCLUSION: The incidence of cough related to the type 1 Ang II receptor antagonist losartan is significantly lower than that observed with lisinopril, and similar to that observed with hydrochlorothiazide in patients with a rechallenged ACE inhibitor cough. Losartan 84-92 angiotensin I converting enzyme Homo sapiens 238-241 8315516-7 1993 EFFECT OF LOSARTAN: The novel angiotensin II blocker losartan has, like ACE inhibitors, shown significant effects on cardiovascular structure in animal models. Losartan 53-61 angiotensin I converting enzyme Homo sapiens 72-75 8391072-2 1993 Since ACE inactivates bradykinin in addition to its action on angiotensin I we hypothesized that losartan and enalapril have different effects on the response to angiotensin and bradykinin. Losartan 97-105 angiotensin I converting enzyme Homo sapiens 6-9 34529122-11 2021 Losartan and metoprolol, but not enalapril, upregulated ACE expression in endothelial cells, accordingly with higher levels of sACE2 in patients using these drugs. Losartan 0-8 angiotensin I converting enzyme Homo sapiens 56-59 24131339-5 2013 Losartan was also able to inhibit ACE whatever the substrate tested, with IC50 of micromolar range (17.13-146 muM). Losartan 0-8 angiotensin I converting enzyme Homo sapiens 34-37 18768350-0 2008 Design of the heart failure endpoint evaluation of AII-antagonist losartan (HEAAL) study in patients intolerant to ACE-inhibitor. Losartan 66-74 angiotensin I converting enzyme Homo sapiens 115-118 20075934-0 2010 One-year effectiveness and safety of open-label losartan/hydrochlorothiazide combination therapy in Japanese patients with hypertension uncontrolled with ARBs or ACE inhibitors. Losartan 48-56 angiotensin I converting enzyme Homo sapiens 162-165 19591299-5 2009 Losartan/HCTZ combination tablets effectively reduce BP when switched from the usual dose of ARB or ACE inhibitors. Losartan 0-8 angiotensin I converting enzyme Homo sapiens 100-103 23106890-11 2012 CONCLUSION: The results of this post hoc analysis in Chinese subjects, although not powered to show significance, were generally consistent with the main study results, which demonstrated a significantly reduced risk of all cause death or hospitalization for heart failure with daily losartan 150 mg vs. losartan 50 mg in subjects with symptomatic heart failure and intolerance to ACE inhibitors, supporting the use of the higher dose for optimum clinical benefit. Losartan 284-292 angiotensin I converting enzyme Homo sapiens 381-384 20830509-9 2011 However, the greatest benefit effect of losartan therapy on ACE activity was observed only in macroalbuminuric patients with DD genotype compared to that in normoalbuminuric patients (61.0 vs. 109.0 IU/l, P = 0.06). Losartan 40-48 angiotensin I converting enzyme Homo sapiens 60-63 20436124-0 2010 Randomised controlled trial: Compared with low-dose losartan, high-dose losartan decreases risk of death or hospital admission for heart failure in people with heart failure who are intolerant to ACE inhibitors. Losartan 72-80 angiotensin I converting enzyme Homo sapiens 196-199 19922995-13 2009 INTERPRETATION: Losartan 150 mg daily reduced the rate of death or admission for heart failure in patients with heart failure, reduced left-ventricular ejection fraction, and intolerance to ACE inhibitors compared with losartan 50 mg daily. Losartan 16-24 angiotensin I converting enzyme Homo sapiens 190-193 18768350-6 2008 CONCLUSIONS: The results of HEAAL should facilitate selection of an optimal dosing regimen for losartan in patients with symptomatic heart failure who are intolerant of ACE-inhibitors. Losartan 95-103 angiotensin I converting enzyme Homo sapiens 169-172 18405793-4 2008 However,this report describes the reverse: a case of losartan-induced cough th hat co om completely resolved after it was substituted with an ACE inhibitor, enalapril. Losartan 53-61 angiotensin I converting enzyme Homo sapiens 142-145 18199798-10 2008 In conclusion, proteinuric type 2 diabetic patients with the D allele of the ACE gene have an unfavorable renal prognosis, which can be mitigated and even improved by losartan. Losartan 167-175 angiotensin I converting enzyme Homo sapiens 77-80 18405793-11 2008 CONCLUSION: This report describes a young woman who developed cough while receiving losartan treatment,which resolved after substitution with the ACE inhibitor enalapril. Losartan 84-92 angiotensin I converting enzyme Homo sapiens 146-149 16128369-13 2005 CONCLUSIONS: Addition of losartan to the ACE inhibitor therapy in patients with HF improves functional capacity in the long run. Losartan 25-33 angiotensin I converting enzyme Homo sapiens 41-44 16960460-11 2006 CONCLUSION: Our data suggest that losartan provides a similar short-term antiproteinuric response for all three genotypes of ACE I/D genotype in non-diabetic proteinuric chronic renal disease. Losartan 34-42 angiotensin I converting enzyme Homo sapiens 125-128 18360068-10 2008 The antiatherosclerotic effect of losartan on the carotid artery was comparable to that of ACE-inhibitors, and less adverse effects, such as coughing that occurs with ACE inhibitors, were observed. Losartan 34-42 angiotensin I converting enzyme Homo sapiens 167-170 16960460-3 2006 We evaluated the short-term antiproteinuric effect of losartan according to the ACE I/D genotype in patients with non-diabetic proteinuric renal diseases. Losartan 54-62 angiotensin I converting enzyme Homo sapiens 80-83 15080371-0 2004 Angiotensin converting enzyme genotype influences the response to the angiotensin II receptor antagonist losartan in patients with hypertension. Losartan 105-113 angiotensin I converting enzyme Homo sapiens 0-29 15080371-8 2004 The ACE genotype may be a determinant of the response to losartan in hypertensive patients. Losartan 57-65 angiotensin I converting enzyme Homo sapiens 4-7 14996614-3 2004 In studies of dementias and Alzheimer"s disease (AD), some studies have shown that antihypertensive drugs, including angiotensin-converting enzyme inhibitors, have some moderate effects on cognitive decline, but that the angiotensin receptor antagonist losartan has a significantly beneficial effect. Losartan 253-261 angiotensin I converting enzyme Homo sapiens 117-146 12716812-18 2003 CONCLUSIONS: In contrast to previous observational studies with ACE inhibitors, long-term treatment with losartan has similar beneficial renoprotective effects on progression of diabetic nephropathy in hypertensive type 1 diabetic patients with ACE II and DD genotypes. Losartan 105-113 angiotensin I converting enzyme Homo sapiens 245-248 12507410-4 2003 The Losartan Intervention For Endpoint (LIFE) reduction in hypertension study provides additional data to support the use of the ACE inhibitors to lower the risk of stroke among patients with hypertension and vascular diseases. Losartan 4-12 angiotensin I converting enzyme Homo sapiens 129-132